Kymera Therapeutics
400 Technology Square, 10th Floor
Cambridge
Massachusetts
02139
United States
Website: http://www.kymeratx.com/
Email: inquiries@kymeratx.com
About Kymera Therapeutics
Despite recent advances in modern medicine, hundreds of millions of people are affected by acute and chronic diseases with limited or no available treatment options. Kymera is pioneering a game-changing new therapeutic modality with the potential to transform drug discovery and provide breakthrough treatments for previously untreatable diseases.
YEAR FOUNDED:
2016
LEADERSHIP:
Co-Founder & Chairman: Bruce Booth, D. Phil.
Co-Founder & CTO: Nello Mainolfi, Ph.D.
President & CEO: Laurent Audoly, Ph.D.
TECHNOLOGY:
Please click here for Kymera's technology.:
99 articles with Kymera Therapeutics
-
BioSpace Movers & Shakers, May 6
5/6/2022
Biopharma and life sciences companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers. -
Kymera Therapeutics to Share Novel Preclinical Findings Reinforcing the Advantage of IRAK4 Degraders over Kinase Inhibitors as well as First STAT3 Degrader Results in a Preclinical Model of Th17 Inflammation
5/5/2022
Kymera Therapeutics, Inc. (NASDAQ: KYMR), today presented new preclinical results demonstrating that STAT3 degradation alleviates Th17 inflammation and is active in a preclinical animal model of CNS inflammation, and that IRAK4 degradation blocks multiple innate immune signaling pathways across different immune cell types in a manner superior to kinase inhibitors.
-
Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business Update
5/3/2022
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today reported business highlights and financial results for the first quarter ended March 31, 2022.
-
Kymera Therapeutics to Report First Quarter 2022 Results and Announces Participation at Upcoming Investor Conferences
4/19/2022
Kymera Therapeutics, Inc. today announced that the Company will report first quarter 2022 financial results on May 3rd, 2022 and will host a conference call at 8AM ET.
-
Kenneth Frazier, executive chairman and former chief executive officer of Merck, joins former colleagues Roger Perlmutter and Roy Baynes at the well-financed company.
-
Kymera Therapeutics to Participate in Upcoming March 2022 Investor Conferences
3/2/2022
Kymera Therapeutics, Inc. announced that the Company will participate in the following upcoming virtual investor conferences:
-
Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update
2/24/2022
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2021.
-
Kymera Therapeutics to Participate in Upcoming January and February Investor Conferences
1/25/2022
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in the following upcoming virtual investor conferences.
-
BioSpace Movers & Shakers, Jan. 21
1/21/2022
Biopharma and life sciences companies made numerous appointments this week to boards and executive teams. These Movers & Shakers will position the companies for future growth. -
Kymera Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to Board of Directors
1/18/2022
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of John Maraganore, Ph.D. to its Board of Directors.
-
Kymera Therapeutics Announces Key 2022 Goals and Milestones to Support Its Evolution into a Fully Integrated Degrader Medicines Company
1/10/2022
Kymera Therapeutics, Inc., a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, announced its research and development goals and key milestones for 2022.
-
Kymera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022
1/4/2022
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the Company will present at the virtual 40th Annual J.P. Morgan Healthcare Conference at 9:00 a.m. ET / 6:00 a.m. PT on Tuesday, January 11, 2022.
-
In addition to showcasing data from their in-progress Phase I clinical trial, Kymera Therapeutics also announced their newest development program and outlined the company’s 5-year plan in their very first R&D Day.
-
Kymera Discloses New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Platform and Discovery Updates, and Outlines 5-year Vision and Goals at 2021 R&D Day
12/16/2021
Kymera Therapeutics, Inc. today announced significant advances across its clinical stage pipeline, new programs and platform investments at its first R&D Day.
-
Kymera Therapeutics Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor Malignancies at 63rd American Society of Hematology (ASH) Annual Meeting
12/13/2021
Two presentations demonstrated Kymera’s STAT3 degraders can reduce STAT3 expression, modify STAT3-dependent signaling, and suppress the growth of tumors in multiple preclinical models of lymphoma and solid tumors.
-
Kymera Therapeutics Strengthens Leadership Team with the Appointment of Vijay Sabesan as Senior Vice President, Technical Operations
12/6/2021
Kymera Therapeutics, Inc. today announced the appointment of Vijay Sabesan as Senior Vice President, Technical Operations.
-
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413
11/30/2021
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for its IRAKIMiD degrader, KT-413.
-
Avilar Therapeutics officially joined the game with $60 million in seed financing from RA Capital Management.
-
Kymera Therapeutics to Host Virtual R&D Day on December 16, 2021
11/17/2021
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced it will host a virtual R&D Day for analysts and investors that will be held on Thursday, December 16th from 8:30 a.m. to 11:00 a.m. ET.
-
Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
11/12/2021
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today presented new preclinical data from its STAT3 degrader program at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting.